0001193125-26-059886.txt : 20260219 0001193125-26-059886.hdr.sgml : 20260219 20260219190629 ACCESSION NUMBER: 0001193125-26-059886 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260218 FILED AS OF DATE: 20260219 DATE AS OF CHANGE: 20260219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ceesay Abraham CENTRAL INDEX KEY: 0001722140 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42121 FILM NUMBER: 26656103 MAIL ADDRESS: STREET 1: C/O SCPHARMACEUTICALS, INC. STREET 2: 2400 DISTRICT AVENUE SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01830 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rapport Therapeutics, Inc. CENTRAL INDEX KEY: 0002012593 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 880724208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-321-8020 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2026-02-18 0002012593 Rapport Therapeutics, Inc. RAPP 0001722140 Ceesay Abraham RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100 BOSTON MA 02110 true true false false Chief Executive Officer true Common Stock 2026-02-18 4 S false 3552 29.0516 D 558528 D Common Stock 2026-02-18 4 S false 2281 29.7983 D 556247 D Common Stock 2026-02-18 4 S false 2983 29.0443 D 22829 I By Dorothy Ceesay Irrevocable Trust Common Stock 2026-02-18 4 S false 2100 29.7965 D 20729 I By Dorothy Ceesay Irrevocable Trust Common Stock 81729 I By Ceesay Family Irrevocable Trust These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ Troy Ignelzi, Attorney-in-Fact 2026-02-19